Ep138: Amyloid busters- the benefit and the burden

About this episode

The episode discusses the recent approval of amyloid-targeting therapies for Alzheimer's dementia in Australia and their modest impact on disease progression.

Australia has just approved a second amyloid-targeting therapy for patients with incipient Alzheimer’s dementia. Lecanemab (Leqembi) now joins donanemab (Kisunla) on the Australian Registry of Therapeutic Goods but the impact of both has been modest in Phase III trials to date. After 18 months of therapy they delay progression of disease, as quantified on neurocognitive tests, by around 5 months on average. For some, the prolonged independence and dignity will justify the $60,000...

Topics covered

• health
• medicine
• Alzheimer's
• therapy
• clinical trials

Keywords

• amyloid-targeting therapy
• Lecanemab
• donanemab
• Alzheimer’s dementia
• Phase III trials
• neurocognitive tests
• disease progression
• independence
• dignity
• $60,000

Mentioned in this episode

Products: Lecanemab, donanemab, Kisunla

Places: Australia

More episodes of Pomegranate Health

• Ep149: Could it be syphilis? · June 1, 2026 · 43 min
• [Contagious Conversations] Responding to vaccine hesitancy · May 4, 2026 · 51 min
• REWIND<< Genomics for the generalist · April 21, 2026 · 49 min
• Ep146: Dealing with the next pandemic 2- lockdowns and human rights · April 5, 2026 · 57 min
• Ep145: Dealing with the next pandemic 1- border closures and vaccine mandates · March 30, 2026 · 1h 7m
• [Case Report] 62yo undergoing procedure for a lung nodule · March 15, 2026 · 26 min